The Xcelera R2.2 upgrade is a new version of the Xcelera multimodality cardiology image management, analysis and reporting solution, designed to offer enhanced functionality and greater workflow efficiency.

AngioScore Inc. has introduced longer and larger AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD).

TRUMPF Medical Systems Inc. offers an in-light high-definition (HD) operating room camera, the TruVidia HD, which reportedly captures and transmits razor sharp, true-to-life images. The camera offers a 1,080-line horizontal resolution and 2 million pixels. The images are said to be more than twice as clear as those available from standard definition cameras.

MAQUET Cardiovascular launched HEARTSTRING III Proximal Seal System for coronary artery bypass surgery procedures, a proximal seal technology that allows surgeons to perform coronary artery bypass grafts without the use of a partial occlusion clamp during beating heart surgery.

Cook Medical has received approval from the FDA for its Zenith TX2 Thoracic TAA Endovascular Graft, marking the expansion of Cook Medical’s portfolio of devices to treat aortic diseases.

Boston Scientific launched its Atlantis 018 Peripheral Imaging Catheter, which reportedly brings existing 40MHz coronary standard ultrasound imaging resolution to peripheral interventions.

Vascular Solutions Inc. recently launched the Axis Wire, a 0.035-inch specialty guidewire that combines an extra stiff proximal shaft with a long super-floppy distal tip.

Cook Medical recently launched the EVOLUTION-Shortie Mechanical Dilator Sheath Set, a tool for venous entry during cardiac lead extraction procedures, an extension of the company’s EVOLUTION mechanical extraction sheath technology.

The FDA has cleared Medtronic’s Attain StarFix OTW (over-the-wire) lead (Model 4195), an active fixation left-heart lead for cardiac resynchronization therapy (CRT).

The FDA recently cleared Boston Scientific Corp.’s PROMUS Everolimus-Eluting Coronary Stent System and Abbott Vascular’s XIENCE V Everolimus Eluting Coronary Stent System, both for the treatment of coronary artery disease.

The PROMUS Stent is a private labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant Corp. by Boston Scientific.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now